FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1979196695> ?p ?o ?g. }

• W1979196695 endingPage "133" @default.
• W1979196695 startingPage "125" @default.
• W1979196695 abstract "Postmenopausal women with advanced breast cancer recurring/progressing on or after initial (adjuvant or first-line) endocrine therapy may be treated multiple times with one of several endocrine or combinatorial targeted treatment options before initiating chemotherapy. In the absence of direct head-to-head comparisons of these treatment options, an indirect comparison can inform treatment choice. This network meta-analysis compared the efficacy of everolimus plus exemestane with that of fulvestrant 250 and 500 mg in the advanced breast cancer setting following adjuvant or first-line endocrine therapy. The reported hazard ratios (HRs) for progression-free survival (PFS) or time to progression from six studies that formed a network to compare everolimus plus exemestane (BOLERO-2 trial) with fulvestrant were analyzed by means of a Bayesian network meta-analysis. In the primary comparison (PFS analysis based on the local review of disease progression from BOLERO-2 with the data from the other studies), everolimus plus exemestane appeared to be more efficacious than both fulvestrant 250 mg (HR = 0.47; 95 % credible interval [CrI] 0.38–0.58) and 500 mg (HR = 0.59; 95 % CrI 0.45–0.77). Similar results were obtained in an alternate comparison based on central review of disease progression from BOLERO-2 with the data from the other studies (HR = 0.40; 95 % CrI 0.31–0.51 and HR = 0.50; 95 % CrI 0.37–0.67, respectively), and in a subgroup analysis of patients who had received prior aromatase inhibitor therapy (HR = 0.47; 95 % CrI 0.38–0.58 and HR = 0.55; 95 % CrI 0.40–0.76, respectively). These results suggest that everolimus plus exemestane may be more efficacious than fulvestrant in patients with advanced breast cancer who progress on or after adjuvant or first-line therapy with a nonsteroidal aromatase inhibitor." @default.
• W1979196695 created "2016-06-24" @default.
• W1979196695 creator A5003504334 @default.
• W1979196695 creator A5004521061 @default.
• W1979196695 creator A5032175884 @default.
• W1979196695 creator A5041410352 @default.
• W1979196695 creator A5071675004 @default.
• W1979196695 creator A5072355812 @default.
• W1979196695 creator A5073501391 @default.
• W1979196695 creator A5080272475 @default.
• W1979196695 date "2013-11-24" @default.
• W1979196695 modified "2023-09-27" @default.
• W1979196695 title "Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis" @default.
• W1979196695 cites W1781289545 @default.
• W1979196695 cites W2032144589 @default.
• W1979196695 cites W2049265027 @default.
• W1979196695 cites W2053922367 @default.
• W1979196695 cites W2063538932 @default.
• W1979196695 cites W2102620699 @default.
• W1979196695 cites W2104561097 @default.
• W1979196695 cites W2113458582 @default.
• W1979196695 cites W2125776201 @default.
• W1979196695 cites W2127622911 @default.
• W1979196695 cites W2129958055 @default.
• W1979196695 cites W2138692147 @default.
• W1979196695 cites W2142334766 @default.
• W1979196695 cites W2149615486 @default.
• W1979196695 cites W2167188058 @default.
• W1979196695 cites W2171244965 @default.
• W1979196695 cites W4232041672 @default.
• W1979196695 cites W4234749243 @default.
• W1979196695 doi "https://doi.org/10.1007/s10549-013-2778-5" @default.
• W1979196695 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3889833" @default.
• W1979196695 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24272078" @default.
• W1979196695 hasPublicationYear "2013" @default.
• W1979196695 type Work @default.
• W1979196695 sameAs 1979196695 @default.
• W1979196695 citedByCount "33" @default.
• W1979196695 countsByYear W19791966952014 @default.
• W1979196695 countsByYear W19791966952015 @default.
• W1979196695 countsByYear W19791966952016 @default.
• W1979196695 countsByYear W19791966952017 @default.
• W1979196695 countsByYear W19791966952018 @default.
• W1979196695 countsByYear W19791966952019 @default.
• W1979196695 countsByYear W19791966952020 @default.
• W1979196695 crossrefType "journal-article" @default.
• W1979196695 hasAuthorship W1979196695A5003504334 @default.
• W1979196695 hasAuthorship W1979196695A5004521061 @default.
• W1979196695 hasAuthorship W1979196695A5032175884 @default.
• W1979196695 hasAuthorship W1979196695A5041410352 @default.
• W1979196695 hasAuthorship W1979196695A5071675004 @default.
• W1979196695 hasAuthorship W1979196695A5072355812 @default.
• W1979196695 hasAuthorship W1979196695A5073501391 @default.
• W1979196695 hasAuthorship W1979196695A5080272475 @default.
• W1979196695 hasBestOaLocation W19791966951 @default.
• W1979196695 hasConcept C121608353 @default.
• W1979196695 hasConcept C126322002 @default.
• W1979196695 hasConcept C143998085 @default.
• W1979196695 hasConcept C207103383 @default.
• W1979196695 hasConcept C2775860665 @default.
• W1979196695 hasConcept C2775930923 @default.
• W1979196695 hasConcept C2776166826 @default.
• W1979196695 hasConcept C2776215463 @default.
• W1979196695 hasConcept C2777176818 @default.
• W1979196695 hasConcept C2778504769 @default.
• W1979196695 hasConcept C2778812593 @default.
• W1979196695 hasConcept C2779699572 @default.
• W1979196695 hasConcept C2780482068 @default.
• W1979196695 hasConcept C44249647 @default.
• W1979196695 hasConcept C530470458 @default.
• W1979196695 hasConcept C71924100 @default.
• W1979196695 hasConceptScore W1979196695C121608353 @default.
• W1979196695 hasConceptScore W1979196695C126322002 @default.
• W1979196695 hasConceptScore W1979196695C143998085 @default.
• W1979196695 hasConceptScore W1979196695C207103383 @default.
• W1979196695 hasConceptScore W1979196695C2775860665 @default.
• W1979196695 hasConceptScore W1979196695C2775930923 @default.
• W1979196695 hasConceptScore W1979196695C2776166826 @default.
• W1979196695 hasConceptScore W1979196695C2776215463 @default.
• W1979196695 hasConceptScore W1979196695C2777176818 @default.
• W1979196695 hasConceptScore W1979196695C2778504769 @default.
• W1979196695 hasConceptScore W1979196695C2778812593 @default.
• W1979196695 hasConceptScore W1979196695C2779699572 @default.
• W1979196695 hasConceptScore W1979196695C2780482068 @default.
• W1979196695 hasConceptScore W1979196695C44249647 @default.
• W1979196695 hasConceptScore W1979196695C530470458 @default.
• W1979196695 hasConceptScore W1979196695C71924100 @default.
• W1979196695 hasIssue "1" @default.
• W1979196695 hasLocation W19791966951 @default.
• W1979196695 hasLocation W19791966952 @default.
• W1979196695 hasLocation W19791966953 @default.
• W1979196695 hasLocation W19791966954 @default.
• W1979196695 hasOpenAccess W1979196695 @default.
• W1979196695 hasPrimaryLocation W19791966951 @default.
• W1979196695 hasRelatedWork W1979196695 @default.
• W1979196695 hasRelatedWork W2060548158 @default.
• W1979196695 hasRelatedWork W2087683876 @default.
• W1979196695 hasRelatedWork W2100085165 @default.

• next